444290
MMP Inhibitor V
The MMP Inhibitor V, also referenced under CAS 223472-31-9, controls the biological activity of MMP. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.
别名:
MMP Inhibitor V, (2S,4S)-N-Hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide, ONO-4817
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C22H28N2O6
化学文摘社编号:
分子量:
416.47
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
Storage condition:
OK to freeze, protect from light
Quality Level
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
off-white
solubility
ethanol: 15 mg/mL, DMSO: 30 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
N(O)C(=O)[C@H](C[C@H](NC(=O)c1ccc(cc1)Oc2ccccc2)COCOCC)C
InChI
1S/C22H28N2O6/c1-3-28-15-29-14-18(13-16(2)21(25)24-27)23-22(26)17-9-11-20(12-10-17)30-19-7-5-4-6-8-19/h4-12,16,18,27H,3,13-15H2,1-2H3,(H,23,26)(H,24,25)/t16-,18-/m0/s1
InChI key
HDWWQELUBWGQGA-WMZOPIPTSA-N
General description
An orally active non-peptidyl hydroxamate compound that acts as an effective broad-spectrum inhibitor against MMP-2, -3, -8, -9, -12, -13 (Ki = 0.73, 42, 1.1, 2.1, 0.45, and 1.1 nM, respectively), but not MMP-1 (IC50 = 1.6 µM), MMP-7 (Ki = 2.5 µM), or other serine proteases (no activity against chymotrypsin or plasmin at 100 µM). Widely used in studying MMP-mediated diseases development in vivo. Also reported to block P-LAP secretase activity (≥70% inhibition of P-LAP shedding at 10 µM) that is otherwise not inhibited by TIMP-1/2 in CHO cell cultures in vitro.
Packaging
Packaged under inert gas
Other Notes
Okamoto, Y., et al. 2007. Int. Heart J.48, 369.
Ito, N., et al. 2004. Biochem. Biophys. Res. Commun.314, 1008.
Shiraga, M., et al. 2002. Cancer Res.62, 5967.
Mori, T., et al. 2001. Exp. Biol. Med.226, 429.
Yamada, A., et al. 2000. Inflamm. Res.49, 144.
Ito, N., et al. 2004. Biochem. Biophys. Res. Commun.314, 1008.
Shiraga, M., et al. 2002. Cancer Res.62, 5967.
Mori, T., et al. 2001. Exp. Biol. Med.226, 429.
Yamada, A., et al. 2000. Inflamm. Res.49, 144.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
相关内容
Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.
Søren B van Witteloostuijn et al.
Journal of peptide science : an official publication of the European Peptide Society, 23(12), 845-854 (2017-10-24)
Bariatric surgery is currently the most effective treatment of obesity, which has spurred an interest in developing pharmaceutical mimetics. It is thought that the marked body weight-lowering effects of bariatric surgery involve stimulated secretion of appetite-regulating gut hormones, including glucagon-like
Prem Swaroop Yadav et al.
iScience, 26(9), 107548-107548 (2023-08-28)
Low circulating phosphate (Pi) leads to rickets, characterized by expansion of the hypertrophic chondrocytes (HCs) in the growth plate due to impaired HC apoptosis. Studies in HCs demonstrate that Pi activates the Raf/MEK/ERK1/2 and mitochondrial apoptotic pathways. To determine how
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 444290-2MG | 04055977186079 |